Stockreport

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives [Yahoo! Finance]

PLUS THERAPEUTICS, Inc.  (PSTV) 
PDF Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursem [Read more]